Please wait a minute...
90Life Research  2019, Vol. 2 Issue (4): 152-159    DOI: 10.12032/life2019-1025-302
New advances in immunotherapy for prostate cancer
Hassan Lois Bala1,*()
1International Medical School, Tianjin Medical University, Tianjin, China.
Download: HTML     PDF(235KB)
Export: BibTeX | EndNote (RIS)      


In recent years, prostate cancer has been known to have an increasing incidence worldwide. In 2012, prostate cancer was recognized as the second most frequent cancer to occur in men and fifth leading cause of cancer mortality in men. It is known to affect one of every eight men in the world, and even more common in men above the age of 65. However, the long-term survival rate for an average cancer patient continues to decline, creating a need for therapies that could enhance survival rate with favorable advantages. With the minimal side effects and toxicity of the new treatments, it is obvious that these new treatments are the way forward in fighting cancer. This review elaborates the new therapy for prostate cancer treatment that has been developed in very recent times. The goal is not only to create awareness of these new treatments but also gives patients as well as doctors more treatment options. This review builds a foundation on the knowledge of cancer, importantly cancer immunology, and also forms groundwork majorly on prostate cancer, focusing on the mechanism of how immunotherapy could be a better choice over the previously common prostate cancer treatments, proposing a perspective on future directions in the treatment of prostate cancer.

Key wordsProstate cancer      Immunotherapy      CAR T-cell therapy     
Received: 08 October 2019      Published: 24 October 2019
Corresponding Authors: Lois Bala Hassan   
Cite this article:

Hassan Lois Bala. New advances in immunotherapy for prostate cancer. 90Life Research, 2019, 2(4): 152-159.


URL:     OR

1.   National Cancer Institute. Understanding Cancer. February 9, 2015.
2.   Cancer Research UK. What is Cancer? November 23, 2017.
3.   Newman T. How does cancer evade the immune system? New mechanism revealed, Medical News Today. November 28, 2017.
4.   Euler L. How cancer evades your immune system, and what to do about it. Cancer defeated! January 3, 2018.
5.   Antoni R. Adaptive immune resistance: How cancer protects from immune attack. Cancer Discov. 2015; 5: 915-919.
6.   Prostate cancer. Nurs Stand. 2016; 30: 17.
7.   Daniyal M, Siddiqui ZA, Akram M, et al. Epidemiology, etiology, diagnosis and treatment of prostate cancer. Asian Pac J Cancer Prev. 2014; 15: 9575-9578.
8.   Castillejos-Molina RA, Gabilondo-Navarro FB. Prostate cancer. Salud Publica Mex. 2016; 58: 279-284.
9.   Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries. Int J Urol. 2018; 25: 524-531.
10.   Zhao J, Stockwell T, Roemer A, et al. Is alcohol consumption a risk factor for prostate cancer? A systematic review and meta-analysis. BMC Cancer. 2016; 16: 845.
11.   Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer. 2002; 2: 389-396.
12.   Chakraborty S, Rahman T. The difficulties in cancer treatment. Ecancermedicalscience. 2012; 6: 16.
13.   Gregory K, Laura QM. The evolving role of immune checkpoint inhibitors in cancer treatment. Oncologist. 2015; 20: 812-822.
14.   National Cancer Institute. Biological Therapies for Cancer. April 26, 2018.
15.   National Cancer Institute. T-cell Transfer Therapy. September 24, 2019.
16.   National Cancer Institute. CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancers. July 30, 2019.
17.   Newick K, O' Brien S, Moon E, et al. CAR T Cell Therapy for Solid Tumors. Annu Rev Med. 2017; 68: 139-152.
18.   Thomas S, Prendergast GC. Cancer Vaccines: A Brief Overview. Methods Mol Biol. 2016; 1403: 755-761.
19.   Gatti-Mays ME, Jason MR, Julie MC, et al. Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations. Hum Vaccin Immunother. 2017; 13: 2561-2574.
20.   Aldous AR, Dong JZ. Personalized neoantigen vaccines: A new approach to cancer immunotherapy. Bioorg Med Chem. 2018; 26: 2842-2849.
21.   Pickwell-Smith BA, So AC, Board RE. Managing side effects of cancer immunotherapy for the acute physician. Br J Hosp Med (Lond). 2018; 79: 372-377.
22.   Zhou S, Khanal S, Zhang H. Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients. Ther Clin Risk Manag. 2019; 15: 211-221.
23.   Marlena J, ?ukasz S, Anna K, et al. Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review. J Immunol Res. 2017; 4861570.
24.   Mulders PF, De Santis M, Powles T, et al. Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy. Cancer Immunol Immunother. 2015; 64: 655-663.
25.   Cordes LM, Gulley JL, Madan RA. The evolving role of immunotherapy in prostate cancer. Curr Opin Oncol. 2016; 28: 232-240.
26.   Redman JM, Gulley JL, Madan RA. Combining immunotherapies for the treatment of prostate cancer. Urol Oncol. 2017; 35: 694-700.
27.   Ramakrishnan Geethakumari P, Schiewer MJ, Knudsen KE, et al. PARP Inhibitors in Prostate Cancer. Curr Treat Options Oncol. 2017; 18: 37.
28.   Pezaro CJ, Marciscano AE, Madan RA. The Winds of Change: Emerging Therapeutics in Prostate Cancer. Am Soc Clin Oncol Educ Book. 2018; 38: 382-390.
29.   Bilusic M, Madan RA, Gulley JL.Immunotherapy of Prostate Cancer: Facts and Hopes. Clin Cancer Res. 2017; 23: 6764-6770.
30.   Schepisi G, Cursano MC, Casadei C, et al. CAR-T cell therapy: a potential new strategy against prostate cancer. J Immunother Cancer. 2019; 7: 258.
No related articles found!